n-hydroxy-3,2'-dimethyl-4-aminobiphenyl

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID Source	ID
PubMed CID	108211
MeSH ID	M0129629

Synonyms (13)

Synonym
hydroxylamine, n-(2',3-dimethylbiphenyl-4-yl)-
n-hydroxy-3,2'-dimethyl-4-aminobiphenyl
ccris 6313
2',3-dimethyl-n-hydroxy-(1,1'-biphenyl)-4-amine
brn 2834261
4-n-(3,2'-dimethylbiphenyl)hydroxamine
(1,1'-biphenyl)-4-amine, n-hydroxy-2',3-dimethyl-
(1,1'-biphenyl)-4-amine, 2',3-dimethyl-n-hydroxy-
70786-72-0
unii-ai7fn5evn2
ai7fn5evn2 ,
DTXSID50221046
Q27273937

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	5 (62.50)	18.7374
1990's	2 (25.00)	18.2507
2000's	1 (12.50)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.18 (24.57)
Research Supply Index	2.20 (2.92)
Research Growth Index	4.38 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.18)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	8 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
2-aminofluorene [no description available]	1.97	1
n-hydroxy-2-aminofluorene N-hydroxy-2-aminofluorene: structure	1.97	1
hydroxyacetylaminofluorene Hydroxyacetylaminofluorene: A N-hydroxylated derivative of 2-ACETYLAMINOFLUORENE that has demonstrated carcinogenic action.	1.96	1	2-acetamidofluorenes
quinoxalines quinoxaline : A naphthyridine in which the nitrogens are at positions 1 and 4.	2	1	mancude organic heterobicyclic parent; naphthyridine; ortho-fused heteroarene
4-biphenylamine 4-biphenylamine: used in detection of sulfates, & as a carcinogen in cancer research; RN given refers to parent cpd; structure. biphenyl-4-amine : An aminobiphenyl that is biphenyl substituted by an amino group at position 4.	1.97	1	aminobiphenyl	carcinogenic agent
benzidine benzidine: RN given refers to parent cpd. benzidine : A member of the class of biphenyls that is 1,1'-biphenyl in which the hydrogen at the para-position of each phenyl group has been replaced by an amino group.	1.97	1	biphenyls; substituted aniline	carcinogenic agent
paraoxon [no description available]	2.37	2	aryl dialkyl phosphate; organophosphate insecticide	EC 3.1.1.7 (acetylcholinesterase) inhibitor; mouse metabolite
2',3-dimethyl-4-aminobiphenyl 2',3-dimethyl-4-aminobiphenyl: RN given refers to parent cpd; structure	2.66	3
n-hydroxy-4-aminobiphenyl [no description available]	2.37	2	aminobiphenyl; N-substituted amine	carcinogenic agent; human xenobiotic metabolite
2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine: directly acting genotoxic metabolite of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine. N-hydroxy-PhIP : An imidazopyridine that is 1H--imidazo[4,5-b]pyridine which is substituted at positions 1, 2, and 6 by methyl, hydoxyamino, and phenyl groups, respectively. The active metabolite of the dietary carcinogen PhIP.	2	1	hydroxylamine; imidazopyridine	carcinogenic agent; genotoxin; human xenobiotic metabolite; mouse metabolite; mutagen; neurotoxin; rat metabolite
acetyl coenzyme a Acetyl Coenzyme A: Acetyl CoA participates in the biosynthesis of fatty acids and sterols, in the oxidation of fatty acids and in the metabolism of many amino acids. It also acts as a biological acetylating agent.	7.66	3	acyl-CoA	acyl donor; coenzyme; effector; fundamental metabolite

Condition	Relationship Strength	Studies
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	2.39	2
Bladder Cancer [description not available]	2	1
Cancer of Colon [description not available]	2	1
Cancer of Prostate [description not available]	2.67	3
Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER.	2	1
Carcinoma, Transitional Cell A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.	2	1
Colonic Neoplasms Tumors or cancer of the COLON.	2	1
Hyperplasia An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.	2	1
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	2.67	3
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	1.98	1
Adenoma, Prostatic [description not available]	1.97	1
Prostatic Hyperplasia Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.	1.97	1

chemdatabank.com